Stem Cell Caution
By Richard Hayes,
Tom Paine
| 05. 24. 2006
Support for stem cell research has become a cause célèbre among Democrats. Last year New Jersey Senator Jon Corzine made it a big part of his successful campaign for Governor. This year New York Attorney General Elliott Spitzer is proposing a $1 billion stem cell bond issue as part of his own gubernatorial campaign. In Missouri Democrat Claire McCaskill is spotlighting stem cell research in her effort to unseat Republican Senator Jim Talent. And this week marks the one year anniversary of the passage of Castle-DeGette, the House bill that expands federal funding for stem cell research. Senate Democrats are rallying to push for a vote as soon as possible on the Senate version of this bill.
I'm a life-long liberal Democrat, pro-choice on abortion and a supporter of innovative medical research. I believe that stem cell research holds promise, and that the Bush administration's policies are unnecessarily restrictive. Now stem cells appear to be giving Democrats a potent vote-getting wedge issue.
Why am I worried about this?
I'm worried because in their over-the-top enthusiasm for stem cell and cloning...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...